Alector (ALEC) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Alector (ALEC) over the past year, gaining 32.3% versus a loss of 34.4%. Over five years, GLSI leads with a -59.5% price change compared with -91.3% for ALEC. Alector is the larger company by market cap ($225.5 million vs $222.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | GLSI |
|---|---|---|
| Share price | $2.02 | $15.14 |
| Market cap | $225.55M | $222.23M |
| 1-day change | +5.21% | -1.62% |
| YTD return | +29.49% | -27.94% |
| 1-year return | -34.42% | +32.28% |
| 5-year return | -91.33% | -59.46% |
| EPS (TTM) | $-1.09 | $-1.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $34.10 |
| 52-week low | $1.09 | $7.78 |
| Distance from 52-week high | -40.59% | -55.60% |
| Analyst consensus | hold | none |
| Avg. price target upside | +63.37% | +276.49% |
| Average volume | 2.86M | 138.91K |
| Shares outstanding | 111.66M | 14.68M |
| Employees | 103 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed ALEC by 66.7 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Healthcare · Biotechnology · 103 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Healthcare · Biotechnology
ALEC vs GLSI FAQ
Which is bigger, Alector or Greenwich LifeSciences?
Alector (ALEC) is larger, with a market capitalization of $225.55M compared with $222.23M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, ALEC or GLSI?
GLSI returned +32.28% over the past 12 months, compared with -34.42% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.